Clinical Trials Logo
  1. Home
  2. Chronic Hepatitis C Virus
  3. NCT02945228

Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2

Chronic Hepatitis C Virus Clinical Trial

Official title:
Drug Use-Results Survey in Patients Infected With Hepatitis C Virus Genotype 2

Clinical Trial Summary

The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir with ribavirin used for participants infected with chronic hepatitis C virus (HCV) genotype 2 in daily practice in Japan.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02945228
Study type Observational
Source AbbVie
Contact
Status Completed
Phase
Start date October 26, 2016
Completion date July 26, 2019
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT02806362 - Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD) Phase 3
Withdrawn NCT01691235 - SIMpill Medication Dispensing Device in the Treatment of HCV N/A
Completed NCT01701401 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV Phase 3
Completed NCT01726517 - Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects Phase 2
Completed NCT01740791 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection Phase 1
Recruiting NCT05904470 - A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Phase 2
Completed NCT01851330 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3) Phase 3
Completed NCT01852604 - Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) Phase 2
Completed NCT02105467 - Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060) Phase 3
Recruiting NCT02038387 - Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD) N/A
Completed NCT01581138 - VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C Phase 2
Completed NCT02629172 - Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1
Completed NCT01768286 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection Phase 3
Completed NCT01686789 - Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4 Phase 4
Completed NCT00610597 - Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease N/A
Completed NCT02707952 - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection Phase 3
Completed NCT01516918 - A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis Phase 2
Completed NCT02723084 - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection Phase 3